UKCF gene therapy consortium tracking study: Sputum and serum calprotectin are useful novel measurements in CF exacerbation

UKCF gene therapy consortium tracking study: Sputum and serum calprotectin are useful novel measurements in CF exacerbation

Bibliographic Details
Main Authors:	Gray, R, Horsley, A, Macleod, K, Imrie, M, Dewar, M, Voase, N, Donovan, J, Hyde, S, Gill, D, Griesenbach, U, Davies, J, Alton, E, Boyd, A, Porteous, D, Cunningham, S, Innes, J, Greening, A
Format:	Journal article
Published:	2007

Similar Items

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
by: Davies, J, et al.
Published: (2009)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
by: Alton, E, et al.
Published: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
by: Alton, E, et al.
Published: (2012)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
by: Davies, J, et al.
Published: (2009)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
by: Alton, E, et al.
Published: (2012)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
by: Griesenbach, U, et al.
Published: (2011)

EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH CF: DATA FROM THE UK CF GENE THERAPY CONSORTIUM (UKCFGTC) 'RUN-IN' STUDY
by: Saunders, C, et al.
Published: (2010)

A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF
by: Alton, E, et al.
Published: (2013)

Genetic medicines for CF: Hype versus reality
by: Alton, E, et al.
Published: (2016)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
by: Davies, J, et al.
Published: (2011)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY
by: Alton, E, et al.
Published: (2010)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS: THE RUN-IN STUDY
by: Alton, E, et al.
Published: (2010)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
by: Alton, E, et al.
Published: (2013)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
by: Alton, E, et al.
Published: (2013)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
by: Hyde, S, et al.
Published: (2015)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
by: Davies, G, et al.
Published: (2011)

Delivery of genes into the CF airway
by: Gill, D, et al.
Published: (2014)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
by: Gill, DR, et al.
Published: (2010)

Self-reactive CFTR T cells in humans: implications for gene therapy.
by: Calcedo, R, et al.
Published: (2013)

Moving lentiviral-based gene therapy into a first-in-man CF trial
by: Griesenbach, D, et al.
Published: (2015)

ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study
by: Desmond M Murphy, et al.
Published: (2023-11-01)

Calprotectin in systemic vasculitis
by: Pathare, S, et al.
Published: (2006)

Calprotectin in Lung Diseases
by: Ourania S. Kotsiou, et al.
Published: (2021-02-01)

CLINICAL SIGNIFICANCE OF CALPROTECTIN IN RHEUMATIC DISEASES
by: A. S. Avdeeva
Published: (2018-09-01)

Ascitic fluid calprotectin and ratio of calprotectin to total protein in spontaneous bacterial peritonitis
by: Mai Mustafa Fahmy, et al.
Published: (2023-05-01)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
by: Alton, E, et al.
Published: (2014)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
by: Alton, E, et al.
Published: (2014)

Assessment of CFTR function after gene transfer in vitro and in vivo.
by: Griesenbach, U, et al.
Published: (2008)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
by: Alton, E, et al.
Published: (2012)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
by: Alton, E, et al.
Published: (2012)

A randomized, double-blind, placebo-controlled trial of repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis
by: Alton, E, et al.
Published: (2015)

Fecal calprotectin and microbiota of the gut
by: V. G. Gorokhova, et al.
Published: (2016-07-01)

Fecal Calprotectin Is Increased in Stroke
by: Shin Young Park, et al.
Published: (2021-12-01)

LASER-INDUCED FLUORESCENCE DETECTION OF CF AND CF2 RADICALS IN A CF4/O2 PLASMA
by: Booth, J, et al.
Published: (1987)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
by: Pytel, K, et al.
Published: (2016)

Sputum cytology in suspected cases of carcinoma of lung (Sputum cytology a poor man′s bronchoscopy!)
by: A S Ammanagi, et al.
Published: (2012-01-01)

Post-translational modifications on the metal-sequestering protein calprotectin
by: Nolan, Elizabeth M., et al.
Published: (2023)

Temporal regulation of CFTR expression during ovine lung development: implications for CF gene therapy.
by: Broackes-Carter, F, et al.
Published: (2002)

THE STRUCTURE OF SOLID CF3I
by: Clarke, S, et al.
Published: (1993)

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation
by: Horsley, A, et al.
Published: (2013)